Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

The 14th St Gallen International Breast Cancer Conference (2015) reviewed new evidence on locoregional and systemic therapies for early breast cancer. This manuscript presents news and progress since the 2013 meeting, provides expert opinion on almost 200 questions posed to Consensus Panel members, and summarizes treatment-oriented classification of subgroups and treatment recommendations.

[1]  D. Berry,et al.  Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Dowsett,et al.  Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. , 2015, Breast.

[3]  G. Hortobagyi,et al.  Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Paik,et al.  Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. , 2014 .

[5]  T. Whelan,et al.  NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Narod.  The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer , 2011, Breast Cancer Research and Treatment.

[7]  C. Hudis,et al.  ASCO's approach to a learning health care system in oncology. , 2013, Journal of oncology practice.

[8]  A. Giobbie-Hurder,et al.  Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.

[9]  D. Bowtell,et al.  Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. , 2015, Cancer research.

[10]  A. Goldhirsch,et al.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. , 2014, Breast.

[11]  A. Schneeweiss,et al.  Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study , 2014, Breast Cancer Research.

[12]  A. Di Leo,et al.  Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. , 2015, Breast.

[13]  J. Forbes,et al.  Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. , 2015, The New England journal of medicine.

[14]  S. Hilsenbeck,et al.  An epigenomic approach to therapy for tamoxifen-resistant breast cancer , 2014, Cell Research.

[15]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[16]  M. Rezai,et al.  Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy , 2015, Annals of Surgical Oncology.

[17]  M. Rezai,et al.  Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. , 2014 .

[18]  Mark T. W. Ebbert,et al.  PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers , 2012, BMC Medical Genomics.

[19]  D. Berry,et al.  Neoadjuvant as Future for Drug Development in Breast Cancer—Response , 2016, Clinical Cancer Research.

[20]  Seema A. Khan,et al.  Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer , 2014, Annals of Surgical Oncology.

[21]  N. Rahman,et al.  Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012) , 2015 .

[22]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Whelan,et al.  NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[26]  N. Houssami,et al.  Margins in breast conservation: A clinician's perspective and what the literature tells us , 2014, Journal of surgical oncology.

[27]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[28]  Thomas Bachelot,et al.  Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.

[29]  S. Gomez,et al.  Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. , 2014, JAMA.

[30]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[31]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Loibl.  PG 8.01 Primary systemic therapy for clinicians: medical and research perspectives , 2015 .

[35]  C. Denkert.  PG 7.04 Developing Ki67 as a useful marker , 2015 .

[36]  M. Dowsett,et al.  Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Pusztai,et al.  Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer , 2015 .

[38]  R. Greil,et al.  The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients , 2013, British Journal of Cancer.

[39]  G. Curigliano.  PG 4.02 Immune pathways and immunome as a target , 2015 .

[40]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[41]  S. Glück,et al.  Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy , 2014, Medical Oncology.

[42]  E. Paci,et al.  Ki67 in breast cancer: a useful prognostic marker? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Hopper,et al.  Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Neumayer,et al.  Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  B. Nordenskjöld,et al.  No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[47]  M. Dieci,et al.  254OACTIVITY OF NEOADJUVANT LAPATINIB (L) PLUS TRASTUZUMAB (T) FOR EARLY BREAST CANCER (EBC) ACCORDING TO PIK3CA MUTATIONS: PATHOLOGICAL COMPLETE RESPONSE (PCR) RATE IN THE CHERLOB STUDY AND POOLED ANALYSIS OF RANDOMIZED TRIALS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[49]  D. Winchester,et al.  Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002 , 2013, Breast Cancer Research and Treatment.

[50]  A. Coates.  PG 0.1 Evolution of the St.Gallen Consensus process for the optimal treatment of women with breast cancer , 2015 .

[51]  L. Hartmann,et al.  Atypical hyperplasia of the breast--risk assessment and management options. , 2015, The New England journal of medicine.

[52]  J. Reis-Filho,et al.  PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa , 2015 .

[53]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[54]  J. Yarnold,et al.  Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues. , 2015, Breast.

[55]  M. Rezai,et al.  The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  M. Ewertz,et al.  Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. , 2015, European journal of cancer.

[57]  L. Boni,et al.  Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. , 2011, JAMA.

[58]  H. Bartelink,et al.  OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925. , 2014 .

[59]  Yi Zhang,et al.  Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence , 2013, Clinical Cancer Research.

[60]  M. Clemons,et al.  Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research , 2013, Breast Cancer Research and Treatment.

[61]  C. Perou,et al.  Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. , 2013, The oncologist.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[63]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[64]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[65]  J. Baselga.  Targeting PIK3CA pathway , 2017 .

[66]  Anton Belousov,et al.  Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study , 2014, Clinical Cancer Research.

[67]  E. Winer,et al.  Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  G. Viale.  A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. , 2015, Breast.

[69]  C. Denkert,et al.  Reply to Ki67 in breast cancer: a useful prognostic marker! , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[71]  M. S. Thomsen,et al.  CT-planned internal mammary node radiotherapy in the DBCG-IMN study: Benefit versus potentially harmful effects , 2014, Acta oncologica.

[72]  J Bogaerts,et al.  High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  S. Fox,et al.  Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer , 2013, British Journal of Cancer.

[74]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[76]  R. Gelber,et al.  Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po , 2015 .

[77]  T. Fehm,et al.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. , 2013, The Lancet. Oncology.

[78]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Sung-Bae Kim,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.

[80]  R. Greil,et al.  Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  V. Galimberti.  PG 9.02 Feasibility of sentinel node biopsy in breast cancer after neoadjuvant treatment , 2015 .

[82]  John M S Bartlett,et al.  An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.

[83]  B. Haffty,et al.  Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer , 2010 .

[84]  R. Gelber,et al.  Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? , 2015, Breast.

[85]  Seema A Khan,et al.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Kuerer,et al.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). , 2015, Annals of surgery.

[87]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Sean Ferree,et al.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens , 2014, BMC Cancer.

[89]  C. Lawton.  Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial , 2012 .

[90]  Z. Hall.  Cancer , 1906, The Hospital.

[91]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[92]  M. Rezai,et al.  Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Joanne S Haviland,et al.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.

[94]  Jack Cuzick,et al.  Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer , 2013, Journal of the National Cancer Institute.

[95]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[96]  T. Whelan.  PG 10.02 Evolving standards in breast cancer radiotherapy: who should receive locoregional RT? , 2015 .

[97]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[98]  U. Güth,et al.  Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[99]  G. Plitas,et al.  Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy , 2013, Annals of Surgical Oncology.

[100]  S. Martino,et al.  Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  E. Perez,et al.  Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit , 2015 .

[103]  M. Zucchetti,et al.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[105]  E. Perez,et al.  Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[107]  James M Ford,et al.  Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Carsten Denkert,et al.  Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study , 2014, Clinical Cancer Research.

[109]  B. Nordenskjöld,et al.  No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. , 2015 .

[110]  P. Campbell.  PG 2.01 Interpreting genomics data at a functional level: What are we learning from large molecular screening projects? , 2015 .

[111]  A. Schneeweiss,et al.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  P. Ellis,et al.  Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.

[113]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[114]  J. Forbes,et al.  Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  H Tesch,et al.  Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[117]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[119]  Anne Wallace,et al.  The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer , 2015, Clinical Cancer Research.

[120]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[121]  R. Gelber,et al.  Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX , 2012, Breast Cancer Research.